If you searched “MOTS-c before and after,” you were probably hoping to see dramatic transformation photos: leaner physiques, side-by-side body shots, or testimonials promising rapid fat loss. We want to be straight with you from the start. dosagepeptide.com does not publish before-and-after photos, testimonials, or promised results for MOTS-c. MOTS-c is referenced here strictly as a research compound, and the honest reason we do not show transformations is simple: the published human evidence to support them does not exist yet. What does exist is a body of laboratory research (mostly in mice) that documents a measurable time-course of effects. This page walks through what those studies actually measured, so you can set expectations grounded in data rather than marketing.
This is a research reference, not medical advice, and nothing here describes what any product does in people.
What the research shows over time
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded inside the mitochondrial genome. It was first described by Lee and colleagues, who reported that MOTS-c activates the AMPK energy-sensing pathway and, in mice, prevented high-fat-diet-induced obesity as well as age-related and diet-induced insulin resistance (Lee, 2015). Crucially, that was a rodent study. The kind of “transformation” many people associate with MOTS-c was observed in mice, not humans.
The most-cited functional timeline comes from Reynolds and colleagues, who gave MOTS-c to young (2-month), middle-aged (12-month), and old (22-month) mice and reported improved physical performance across all ages. In that study, late-life intermittent dosing (about three times per week) increased running capacity and measures of healthspan (Reynolds, 2021). Again, this was in mice.
Human data is thinner and different in kind. Rather than injecting MOTS-c, human studies have mostly measured the body’s own MOTS-c levels rising in response to exercise. Dieli-Conwright and colleagues found that a 16-week aerobic-plus-resistance exercise program raised circulating MOTS-c in one subgroup of breast-cancer survivors, and that the rise correlated with reduced fat mass and improved insulin markers (Dieli-Conwright, 2021). That is an association between exercise-induced endogenous MOTS-c and body composition, not evidence that injecting MOTS-c produces those changes. Reviews of the field reach the same cautious conclusion: exercise reliably raises MOTS-c acutely, but whether administering it reproduces exercise-like benefits in people is unproven (Woodhead & Merry, 2021; Merry, 2020).
| Study | Model | Duration / regimen | What was measured |
|---|---|---|---|
| Lee, 2015 (Cell Metabolism) | Preclinical (mice + cells) | Repeated dosing | Prevented diet-induced obesity and insulin resistance; AMPK activation |
| Reynolds, 2021 (Nature Communications) | Preclinical (mice) | ~3×/week into late life | Improved running/physical capacity and healthspan across ages |
| Dieli-Conwright, 2021 (Scientific Reports) | Human (observational; exercise, not MOTS-c dosing) | 16 weeks of exercise | Endogenous MOTS-c rose; correlated with fat-mass and insulin changes |
Notice the pattern. Every concrete “before and after”-type outcome (fat loss, better insulin sensitivity, more exercise capacity) sits in the preclinical rows. The human row measures a biomarker, not a physique, and it tracks the body’s own response to exercise rather than to an injected peptide.
Realistic expectations
Here is what the data does and does not support. It does support the idea that MOTS-c is a genuine mitochondrial signaling peptide with measurable metabolic effects in animals, and that human exercise raises it. It does not support any specific human timeline. No published study establishes that a person taking MOTS-c will lose a given amount of weight in a given number of weeks, and a 2023 review flatly noted that no effective, validated method for applying MOTS-c in the clinic has yet been developed (Zheng, 2023).
Individual variation is also real and documented. In the exercise study above, the MOTS-c response differed by ethnicity, likely reflecting mitochondrial-DNA differences (Dieli-Conwright, 2021). That alone should make anyone skeptical of a single “before and after” photo standing in for a universal result.
Why are online MOTS-c transformations unreliable? Because they are uncontrolled: no placebo, no verification of what or how much was actually taken, frequent simultaneous changes in diet and training, and strong selection bias toward posting successes. For a research compound with no completed human efficacy trials, a photo is an anecdote, not evidence.
Safety & legal status
Honest bottom line on safety: there is no published human safety data for administered MOTS-c. Animal studies reported tolerability at the doses tested, but rodent tolerability does not establish a human safety profile, a dose ceiling, or long-term risk. The first randomized, double-blind, placebo-controlled human trial designed to formally evaluate injected MOTS-c (a Phase 2a study in adults with prediabetes and overweight/obesity) only began recruiting in 2026, with primary completion projected for 2027 (ClinicalTrials.gov NCT07505745). Until that and similar trials report, human efficacy and safety remain open questions.
MOTS-c is not an approved drug for weight loss, metabolic disease, athletic performance, or any other human use. Materials referenced on this site are for research use only (RUO) and are not intended to diagnose, treat, cure, or prevent any disease, nor for human consumption. Nothing here is medical advice; consult a licensed clinician for health decisions.
Dosage reference
If your interest is the research-handling side (reconstitution and how experimental dosing is expressed in the literature), see our MOTS-c peptide dosage chart per day for a 10 mg vial. To convert vial size, bacteriostatic water volume, and target amounts into per-unit measurements, use our peptide dosage calculator. These are reference tools for research contexts only and are not a recommendation to administer MOTS-c to humans.
FAQ
Are there real before/after photos of MOTS-c?
Not in the peer-reviewed record. There are no published human before-and-after outcome studies of administered MOTS-c. Images circulating online are uncontrolled anecdotes, and we do not host them because the evidence to support them does not exist.
How long until changes appear in studies?
In mice, functional benefits were reported with repeated dosing over weeks, including a roughly three-times-weekly schedule in the healthspan study (Reynolds, 2021). In humans, the only published “timeline” is a 16-week rise in the body’s own MOTS-c during exercise (Dieli-Conwright, 2021), which is not a response to taking the peptide. No human dosing timeline has been established.
Is MOTS-c proven to work in people?
No. Human evidence is currently observational or mechanistic, and the first interventional human trial is only now getting underway (NCT07505745). It would be dishonest to claim proven human results before that data exists.
